Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 3, 2012, Pages 25-32

  Jerabek, Petr ^a   Martinek, Vaclav ^a   Stiborova, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Aristolochic acid; Aristolochic acid nephropathy; Balkan endemic nephropathy; Cytochromes P450 1A1, 1A2 and 1B1, metabolic activation; Molecular modeling

Indexed keywords

ARISTOLOCHIC ACID; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; HEME;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; DNA ADDUCT; ENZYME ANALYSIS; HUMAN; HYDROGEN BOND; KIDNEY DISEASE; PROTEIN BINDING; PROTEIN INTERACTION; REDUCTION;

EID: 84874806270     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, et al. (2002) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101: 500-502.
2. Arlt VM, Levova K, Barta F, Shi Z, Evans JD, Frei E, et al. (2011) Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem Res Toxicol 24: 1710-1719.
3. Arlt VM, Stiborova M, vom Brocke J, Simões ML, Lord GM, Nortier JL, et al. (2007). Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis. 28: 2253-2261.
4. Debelle FD, Vanherweghem J-L and Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74: 158-169. (Pubitemid 351915079)
5. Frisch M, Trucks GW, Schlegel HB, Robb MA and Cheeseman JR (2003) Gaussian 03. Wallingford, CT, USA: Gaussian Inc.
6. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104: 12129-12134. (Pubitemid 47185641)
7. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Cogliano V (2009) A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol 10: 13-14.
8. Huey R, Morris GM, Olson AJ and Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28: 1145-1152. (Pubitemid 46506716)
9. Chen C-H, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. (2012) Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109: 8241-8246.
10. Chen M, Gong L, Qi X, Xing G, Luan Y, Wu Y, et al. (2011) Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci 122: 288-296.
11. Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, et al. (2012) Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 81: 559-567.
12. Kucab JE, Phillips DH, Arlt VM (2010) Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J 277: 2567-2583.
13. Levova K, Moserova M, Kotrbova V, Sulc M, Henderson CJ, Wolf CR, Phillips DH, et al. (2011) Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci 121: 43-56.
14. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, et al. (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43: e11-17.
15. Martinek V, Bren U, Goodman MF, Warshel A and Florian J (2007) DNA polymerase beta catalytic efficiency mirrors the Asn279-dCTP H-bonding strength. FEBS Lett 581: 775-780. (Pubitemid 46216300)
16. Martinek V, Kubickova B, Arlt VM, Frei E, Schmeiser HH, Hudecek J, et al. (2011) Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuroendocrinol Lett 32: 57-70.
17. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelaković B, Wu L, et al. (2011) TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 129: 1532-1536.
18. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 1686-1692. (Pubitemid 30354515)
19. Olivier M, Hollstein M, Schmeiser HH, Straif K and Wild CP (2012) Upper urinary tract urothelial cancers: where it is A:T. Nature Reviews Cancer 12: 503-504.
20. Pontikis G, Borden J, Martinek V and Florián J (2009) Linear energy relationships for the octahedral preference of Mg, Ca and transition metal ions. J Phys Chem A 113: 3588-3593.
21. Poulos T (1995) Cytochrome P450. Curr Opin Struct Biol 5: 767-774.
22. Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A and Grollman AP (2010). Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos. 38: 761-768.
23. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, et al. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282: 14348-14355. (Pubitemid 47100434)
24. Shibutani S, Bonala RR, Rosenquist T, Rieger R, Suzuki N, Johnson F, et al. (2010) Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid la in rodents. Int J Cancer 127: 1021-1027.
25. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C and Cosyns JP (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56: 2025-2028. (Pubitemid 26119902)
26. Schmeiser HH, Stiborova M and Arlt VM (2009) Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel 12: 141-148.
27. Schwede T, Kopp J, Guex N and Peitsch MC (2003) SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 31: 3381-3385. (Pubitemid 37442164)
28. Schyman P, Lai W, Chen H, Wang Y and Shaik S (2011) The directive of the protein: how does cytochrome P450 select the mechanism of dopamine formation? J Am Chem Soc 133: 7977-7984.
29. Sistkova J, Hudecek J, Hodek P, Frei E, Schmeiser HH and Stiborova M (2008) Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuroendocrinol Lett 29: 733-737.
30. Stiborova M, Frei E, Arlt VM and Schmeiser HH (2008a) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658: 55-67. (Pubitemid 351172880)
31. Stiborova M, Frei E, Hodek P, Wiessler M and Schmeiser HH (2005) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113: 189-197. (Pubitemid 39628308)
32. Stiborova M, Frei E and Schmeiser HH (2008b) Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int 73: 1209-1211. (Pubitemid 351693150)
33. Stiborova M, Frei E, Sopko B, Sopkova K, Markova V, Lankova M, et al. (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24: 1695-1703. (Pubitemid 37304677)
34. Stiborova M, Frei E, Wiessler M and Schmeiser HH (2001). Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 14: 1128-1137. (Pubitemid 32800169)
35. Stiborova M, Levova K, Barta F, Shi Z, Frei E, Schmeiser HH, et al. (2012) Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 125: 345-358.
36. Stiborova M, Mares J, Frei E, Arlt VM, Martinek V and Schmeiser HH (2011a) The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen 52: 448-459.
37. Stiborova M, Mares J, Levova K, Pavlickova J, Barta F, Hodek P, et al. (2011b) Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver. Neuro Endocrinol Lett 32 (Suppl 1): 121-130.
38. Stiborova M, Martinek V, Rydlova H, Hodek P and Frei E (2002) Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 62: 5678-5684. (Pubitemid 35204721)
39. 5. Neuroendocrinol Lett 27 Suppl 2: 35-39. (Pubitemid 46534333)
40. Stiborova M, Rupertova M and Frei E (2011c) Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta 1814: 175-185.
41. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al.(1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391. (Pubitemid 23048140)
42. Wang A, Savas U, Stout CD and Johnson EF (2011) Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. J Biol Chem 286: 5736-5743.
43. Xiao Y, Ge M, Xue X, Wang C, Wang H, Wu X, et al. (2008) Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int 73: 1231-1239. (Pubitemid 351693146)
44. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen C-H, Pu Y-S, et al. (2012) Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 25: 1119-1131.